Dawnrays Pharmaceutical (Holdings) Limited
2348.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.44B
Close$
Share Statistics
| Market cap | $1.44 Billion |
|---|---|
| Enterprise Value | $154.98 Million |
| Dividend Yield | $0.06 (6.56%) |
| Earnings per Share | $0.14 |
| Beta | 0.23 |
| Outstanding Shares | 1,504,177,000 |
Return
| Return on Equity | 11.88% |
|---|---|
| Return on Assets | 10.22% |
| Return on Invested Capital | 11.24% |
Valuation & Multiples
| P/E Ratio | 5.36 |
|---|---|
| PEG | 32.83 |
| Price to Sales | 0.96 |
| Price to Book Ratio | 0.48 |
| Enterprise Value to Revenue | 0.07 |
| Enterprise Value to EBIT | 0.39 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 19, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Dawnrays Pharmaceutical (Holdings) Limited
1,074 employees
CEO: Liwei Yu Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and internat...